It’s al­most the end of the road for Fresh Tracks as board sup­ports liq­ui­da­tion

It ap­pears to be al­most clos­ing time for Fresh Tracks Ther­a­peu­tics, as its board ap­proves plans to liq­ui­date and dis­solve the com­pa­ny. The biotech plans to meet with share­hold­ers in the fourth quar­ter to seek con­sent on the plan.

Most em­ploy­ees will be laid off by ear­ly Oc­to­ber, apart from cer­tain staff mem­bers like con­sul­tants and ad­vi­sors who will close up shop. Pres­i­dent and CEO An­drew Sklaw­er will ex­it “with­out cause” by Oct. 2, per an SEC fil­ing. Al­bert Mar­chio II, the com­pa­ny’s chief fi­nan­cial of­fi­cer, will ex­tend his re­mit as the new CEO, as well as sec­re­tary, di­rec­tor and chair­man of the board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.